Cargando…
Diabetic Retinopathy and Inflammation: Novel Therapeutic Targets
Most anti-vascular endothelial growth factor (VEGF) therapies in diabetic macular edema are not as robust as in proliferative diabetic retinopathy. Although the VEGF appears to be a good target in diabetic macular edema, the anti-VEGF therapies appear to be of transient benefit as the edema recurs w...
Autores principales: | Rangasamy, Sampathkumar, McGuire, Paul G., Das, Arup |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277025/ https://www.ncbi.nlm.nih.gov/pubmed/22346115 http://dx.doi.org/10.4103/0974-9233.92116 |
Ejemplares similares
-
Do Genomic Factors Play a Role in Diabetic Retinopathy?
por: Cabrera, Andrea P., et al.
Publicado: (2020) -
Chemokine Mediated Monocyte Trafficking into the Retina: Role of Inflammation in Alteration of the Blood-Retinal Barrier in Diabetic Retinopathy
por: Rangasamy, Sampathkumar, et al.
Publicado: (2014) -
Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?
por: Das, Arup, et al.
Publicado: (2016) -
Genotypes and Phenotypes: A Search for Influential Genes in Diabetic Retinopathy
por: Cabrera, Andrea P., et al.
Publicado: (2020) -
Diabetic retinopathy: Battling the global epidemic
por: Das, Arup
Publicado: (2016)